Yamamoto, Shigeyuki, Ouchi, Yasuomi, Onoe, Hirotaka et al. · Neuroreport · 2004 · DOI
Researchers used brain imaging (PET scans) to study a chemical messenger in the brain called serotonin in ME/CFS patients compared to healthy people. They found that ME/CFS patients had lower levels of serotonin transporters—the proteins that carry serotonin—in a specific brain region called the rostral anterior cingulate. This suggests that serotonin system dysfunction may be involved in ME/CFS symptoms.
This research provides objective neurobiological evidence supporting the involvement of serotonin dysfunction in ME/CFS pathophysiology, moving beyond symptom description to identify brain-level mechanisms. Understanding serotonergic abnormalities may eventually inform targeted therapeutic approaches and help validate ME/CFS as a biological disorder.
This study demonstrates association between reduced serotonin transporters and ME/CFS diagnosis, but does not establish causation—the serotonin abnormality could be a consequence rather than cause of ME/CFS. The findings are specific to one brain region and cannot be generalized to explain all ME/CFS symptoms. The study does not demonstrate that correcting serotonin levels would improve symptoms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.